Daiken Medical Co., Ltd. (TSE:7775) will pay a dividend of ¥9.00 on the 2nd of December. This makes the dividend yield 4.5%, which will augment investor returns quite nicely.
Daiken Medical's Long-term Dividend Outlook appears Promising
We like to see robust dividend yields, but that doesn't matter if the payment isn't sustainable. However, Daiken Medical's earnings easily cover the dividend. As a result, a large proportion of what it earned was being reinvested back into the business.
The next year is set to see EPS grow by 3.6%. If the dividend continues along recent trends, we estimate the payout ratio will be 58%, which is in the range that makes us comfortable with the sustainability of the dividend.
View our latest analysis for Daiken Medical
Daiken Medical's Dividend Has Lacked Consistency
It's comforting to see that Daiken Medical has been paying a dividend for a number of years now, however it has been cut at least once in that time. This suggests that the dividend might not be the most reliable. The dividend has gone from an annual total of ¥21.00 in 2017 to the most recent total annual payment of ¥20.00. Dividend payments have shrunk at a rate of less than 1% per annum over this time frame. A company that decreases its dividend over time generally isn't what we are looking for.
The Dividend Has Growth Potential
With a relatively unstable dividend, it's even more important to evaluate if earnings per share is growing, which could point to a growing dividend in the future. We are encouraged to see that Daiken Medical has grown earnings per share at 5.0% per year over the past five years. A low payout ratio and decent growth suggests that the company is reinvesting well, and it also has plenty of room to increase the dividend over time.
In Summary
Overall, a consistent dividend is a good thing, and we think that Daiken Medical has the ability to continue this into the future. While the payout ratios are a good sign, we are less enthusiastic about the company's dividend record. The payment isn't stellar, but it could make a decent addition to a dividend portfolio.
It's important to note that companies having a consistent dividend policy will generate greater investor confidence than those having an erratic one. Meanwhile, despite the importance of dividend payments, they are not the only factors our readers should know when assessing a company. Taking the debate a bit further, we've identified 2 warning signs for Daiken Medical that investors need to be conscious of moving forward. If you are a dividend investor, you might also want to look at our curated list of high yield dividend stocks.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSE:7775
Daiken Medical
Engages in the manufacture and distribution of medical devices and equipment in Japan and internationally.
Flawless balance sheet with limited growth.
Market Insights
Weekly Picks

The "Sleeping Giant" Stumbles, Then Wakes Up
Swiped Left by Wall Street: The BMBL Rebound Trade

Duolingo (DUOL): Why A 20% Drop Might Be The Entry Point We've Been Waiting For
Recently Updated Narratives

A fully integrated LNG business seems to be ignored by the market.
Hims & Hers Health aims for three dimensional revenue expansion
Endeavour Group's Future PE Expected to Climb to 15.51%
Popular Narratives

A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).
Early mover in a fast growing industry. Likely to experience share price volatility as they scale
